Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088088 · ClinicalTrials.gov registry record · Phase 1
STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by Synta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT00088088: Completed Phase 1 study, sponsored by Synta Pharmaceuticals.
NCT00088088 is a Phase 1 study that has completed, run by Synta Pharmaceuticals. The registered enrollment target is 86 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088088, a Phase 1 study, has completed, sponsored by Synta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
This study is for patients who have Stage IIIb or Stage IV NSCLC and have never had chemotherapy before for their disease. The first phase of the study recently completed and for the second phase of the study patients are randomly assigned to receive either paclitaxel and carboplatin or paclitaxel and carboplatin and study drug (STA 4783). Treatment will be every 3 weeks for 6 cycles.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG STA 4783
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088088
The ClinicalTrials.gov registry entry for NCT00088088 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synta Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00088088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088088 about?
NCT00088088 is a clinical study titled "STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)". This study is for patients who have Stage IIIb or Stage IV NSCLC and have never had chemotherapy before for their disease. The first phase of the study recently completed and for the second phase of the study patients are randomly assigned to receive either paclitaxel and carboplatin or paclitaxel a...
What is the current status of trial NCT00088088?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2004-03. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00088088?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), STA 4783 (DRUG).
Who is sponsoring clinical trial NCT00088088?
This trial is sponsored by Synta Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.